Quick Answer
Ultragenyx Pharmaceutical Inc. reported Total Revenue of $673.00 million for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +20.2% in Total Revenue from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $198.0 thousand | Q4 2017: $2.41 million | Q1 2018: $10.68 million | Q2 2018: $12.79 million | Q3 2018: $11.76 million | Q4 2018: $16.26 million | Q1 2019: $18.17 million | Q2 2019: $24.15 million | Q3 2019: $25.80 million | Q4 2019: $35.59 million | Q1 2020: $36.31 million | Q2 2020: $61.71 million | Q3 2020: $81.47 million | Q4 2020: $91.54 million | Q1 2021: $99.40 million | Q2 2021: $86.98 million | Q3 2021: $81.65 million | Q1 2022: $79.94 million | Q2 2022: $89.34 million | Q3 2022: $90.70 million | Q1 2023: $100.50 million | Q2 2023: $108.31 million | Q3 2023: $98.05 million | Q1 2024: $108.83 million | Q2 2024: $147.03 million | Q3 2024: $139.49 million | Q1 2025: $139.29 million | Q2 2025: $166.50 million | Q3 2025: $159.93 million.
- Over the full 10 years of available data (2016 to 2025), Ultragenyx Pharmaceutical Inc.'s Total Revenue has grown by 505,915.0%.
- Historical annual values: Fiscal year 2025: $673.00 million | Fiscal year 2024: $560.00 million | Fiscal year 2023: $434.00 million | Fiscal year 2022: $363.33 million | Fiscal year 2021: $351.41 million | Fiscal year 2020: $271.03 million | Fiscal year 2019: $103.71 million | Fiscal year 2018: $51.50 million | Fiscal year 2017: $2.61 million | Fiscal year 2016: $133.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: